Cargando…

Real-world evidence studies into treatment adherence, thresholds for intervention and disparities in treatment in people with type 2 diabetes in the UK

PURPOSE: The University of Surrey-Lilly Real World Evidence (RWE) diabetes cohort has been established to provide insights into the management of type 2 diabetes mellitus (T2DM). There are 3 areas of study due to be conducted to provide insights into T2DM management: exploration of medication adhere...

Descripción completa

Detalles Bibliográficos
Autores principales: McGovern, Andrew, Hinton, William, Correa, Ana, Munro, Neil, Whyte, Martin, de Lusignan, Simon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5168506/
https://www.ncbi.nlm.nih.gov/pubmed/27884846
http://dx.doi.org/10.1136/bmjopen-2016-012801
_version_ 1782483357085466624
author McGovern, Andrew
Hinton, William
Correa, Ana
Munro, Neil
Whyte, Martin
de Lusignan, Simon
author_facet McGovern, Andrew
Hinton, William
Correa, Ana
Munro, Neil
Whyte, Martin
de Lusignan, Simon
author_sort McGovern, Andrew
collection PubMed
description PURPOSE: The University of Surrey-Lilly Real World Evidence (RWE) diabetes cohort has been established to provide insights into the management of type 2 diabetes mellitus (T2DM). There are 3 areas of study due to be conducted to provide insights into T2DM management: exploration of medication adherence, thresholds for changing diabetes therapies, and ethnicity-related or socioeconomic-related disparities in management. This paper describes the identification of a cohort of people with T2DM which will be used for these analyses, through a case finding algorithm, and describes the characteristics of the identified cohort. PARTICIPANTS: A cohort of people with T2DM was identified from the Royal College of General Practitioners Research and Surveillance Centre (RCGP RSC) data set. This data set comprises electronic patient records collected from a nationally distributed sample of 130 primary care practices across England with scope to increase the number of practices to 200. FINDINGS TO DATE: A cohort (N=58 717) of adults with T2DM was identified from the RCGP RSC population (N=1 260 761), a crude prevalence of diabetes of 5.8% in the adult population. High data quality within the practice network and an ontological approach to classification resulted in a high level of data completeness in the T2DM cohort; ethnicity identification (82.1%), smoking status (99.3%), alcohol use (93.3%), glycated haemoglobin (HbA1c; 97.9%), body mass index (98.0%), blood pressure (99.4%), cholesterol (87.4%) and renal function (97.8%). Data completeness compares favourably to other, similarly large, observational cohorts. The cohort comprises a distribution of ages, socioeconomic and ethnic backgrounds, diabetes complications, and comorbidities, enabling the planned analyses. FUTURE PLANS: Regular data uploads from the RCGP RSC practice network will enable this cohort to be followed prospectively. We will investigate medication adherence, explore thresholds and triggers for changing diabetes therapies, and investigate any ethnicity-related or socioeconomic-related disparities in diabetes management.
format Online
Article
Text
id pubmed-5168506
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-51685062016-12-22 Real-world evidence studies into treatment adherence, thresholds for intervention and disparities in treatment in people with type 2 diabetes in the UK McGovern, Andrew Hinton, William Correa, Ana Munro, Neil Whyte, Martin de Lusignan, Simon BMJ Open Diabetes and Endocrinology PURPOSE: The University of Surrey-Lilly Real World Evidence (RWE) diabetes cohort has been established to provide insights into the management of type 2 diabetes mellitus (T2DM). There are 3 areas of study due to be conducted to provide insights into T2DM management: exploration of medication adherence, thresholds for changing diabetes therapies, and ethnicity-related or socioeconomic-related disparities in management. This paper describes the identification of a cohort of people with T2DM which will be used for these analyses, through a case finding algorithm, and describes the characteristics of the identified cohort. PARTICIPANTS: A cohort of people with T2DM was identified from the Royal College of General Practitioners Research and Surveillance Centre (RCGP RSC) data set. This data set comprises electronic patient records collected from a nationally distributed sample of 130 primary care practices across England with scope to increase the number of practices to 200. FINDINGS TO DATE: A cohort (N=58 717) of adults with T2DM was identified from the RCGP RSC population (N=1 260 761), a crude prevalence of diabetes of 5.8% in the adult population. High data quality within the practice network and an ontological approach to classification resulted in a high level of data completeness in the T2DM cohort; ethnicity identification (82.1%), smoking status (99.3%), alcohol use (93.3%), glycated haemoglobin (HbA1c; 97.9%), body mass index (98.0%), blood pressure (99.4%), cholesterol (87.4%) and renal function (97.8%). Data completeness compares favourably to other, similarly large, observational cohorts. The cohort comprises a distribution of ages, socioeconomic and ethnic backgrounds, diabetes complications, and comorbidities, enabling the planned analyses. FUTURE PLANS: Regular data uploads from the RCGP RSC practice network will enable this cohort to be followed prospectively. We will investigate medication adherence, explore thresholds and triggers for changing diabetes therapies, and investigate any ethnicity-related or socioeconomic-related disparities in diabetes management. BMJ Publishing Group 2016-11-24 /pmc/articles/PMC5168506/ /pubmed/27884846 http://dx.doi.org/10.1136/bmjopen-2016-012801 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Diabetes and Endocrinology
McGovern, Andrew
Hinton, William
Correa, Ana
Munro, Neil
Whyte, Martin
de Lusignan, Simon
Real-world evidence studies into treatment adherence, thresholds for intervention and disparities in treatment in people with type 2 diabetes in the UK
title Real-world evidence studies into treatment adherence, thresholds for intervention and disparities in treatment in people with type 2 diabetes in the UK
title_full Real-world evidence studies into treatment adherence, thresholds for intervention and disparities in treatment in people with type 2 diabetes in the UK
title_fullStr Real-world evidence studies into treatment adherence, thresholds for intervention and disparities in treatment in people with type 2 diabetes in the UK
title_full_unstemmed Real-world evidence studies into treatment adherence, thresholds for intervention and disparities in treatment in people with type 2 diabetes in the UK
title_short Real-world evidence studies into treatment adherence, thresholds for intervention and disparities in treatment in people with type 2 diabetes in the UK
title_sort real-world evidence studies into treatment adherence, thresholds for intervention and disparities in treatment in people with type 2 diabetes in the uk
topic Diabetes and Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5168506/
https://www.ncbi.nlm.nih.gov/pubmed/27884846
http://dx.doi.org/10.1136/bmjopen-2016-012801
work_keys_str_mv AT mcgovernandrew realworldevidencestudiesintotreatmentadherencethresholdsforinterventionanddisparitiesintreatmentinpeoplewithtype2diabetesintheuk
AT hintonwilliam realworldevidencestudiesintotreatmentadherencethresholdsforinterventionanddisparitiesintreatmentinpeoplewithtype2diabetesintheuk
AT correaana realworldevidencestudiesintotreatmentadherencethresholdsforinterventionanddisparitiesintreatmentinpeoplewithtype2diabetesintheuk
AT munroneil realworldevidencestudiesintotreatmentadherencethresholdsforinterventionanddisparitiesintreatmentinpeoplewithtype2diabetesintheuk
AT whytemartin realworldevidencestudiesintotreatmentadherencethresholdsforinterventionanddisparitiesintreatmentinpeoplewithtype2diabetesintheuk
AT delusignansimon realworldevidencestudiesintotreatmentadherencethresholdsforinterventionanddisparitiesintreatmentinpeoplewithtype2diabetesintheuk